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AbstrAct
Introduction The classical pathway for the diagnosis of 
prostate cancer is transrectal ultrasound-guided (TRUS) 
biopsy of the prostate initiated on the basis of a raised 
prostate-specific antigen (PSA). An alternative pathway is 
to perform multi-parametricMRI (MPMRI) to localise cancer 
and to use this information to influence the decision for, 
and conduct of, a subsequent biopsy, known as an MPMRI-
targeted biopsy. An MPMRI pathway has been shown to 
detect a similar or greater amount of clinically significant 
cancer as TRUS biopsy but has several advantages, 
including the potential to biopsy fewer men with fewer 
cores.
Methods This is a pragmatic, international, multicentre, 
parallel group randomised study in which men are 
allocated in a 1:1 ratio to an MPMRI or TRUS biopsy 
pathway. This study will assess whether an MPMRI-
targeted biopsy approach is non-inferior to a standard 
TRUS biopsy approach in the diagnosis of clinically 
significant cancer. Men in the MRI arm will undergo 
targeted biopsy of suspicious areas only and no biopsy 
will be carried out if the MRI is non-suspicious. Men in 
the TRUS biopsy will undergo a standard 10–12-core 
TRUS biopsy. The main inclusion criteria are a serum 
PSA ≤20 ng/mL, a digital rectal examination finding of 
T2 or less and no prior prostate biopsy. The primary 
outcome is the proportion of men with clinically significant 
cancer detected. A sample size of at least 470 patients is 
required. Key secondary outcomes include the proportion 
of clinically insignificant cancer detected.
Ethics and dissemination Ethical approval was 
obtained from the National Research Ethics Committee 
East Midlands, Leicester (15/EM/0188). Results of 
this study will be disseminated through national and 
international papers. The participants and relevant 
patient support groups will be informed about the results 
of the study.
registration details NCT02380027; Pre-results
study tItlE
Long study title: A multicentre randomised 
controlled trial assessing whether magnetic 
resonance imaging-targeted biopsy is non-in-
ferior to standard transrectal ultrasound 
guided biopsy for the diagnosis of clinically 
significant prostate cancer in men without 
prior biopsy
Short study title: PRostate Evaluation for 
Clinically Important disease: Sampling using 
Image-guidance Or Not? (PRECISION)
Study Acronym: PRECISION
IntroductIon
Prostate cancer is the most common male 
cancer in Europe with an incidence of 370 000 
new cases per year and an incidence in the 
USA of 161 360 new cases per year.1 2 It is the 
second most common cause of cancer death 
in European men, with 90 000 deaths per year 
in Europe and 26 730 deaths per year in the 
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Protocol
strengths and limitations of this study
 ► Randomised trial which mitigates bias and reduces 
chances of observed outcome being influenced by 
confounding factors.
 ► International multicentre study making results more 
generalisable.
 ► Pragmatic design making results more applicable to 
real life clinical practice, thus results can be used to 
change clinical practice.
 ► Pragmatic design introducing more variability in trial 
interventions.
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USA.1 2 A major unmet need in prostate cancer care is 
to better identify men who will benefit from treatment 
while avoiding overtreatment of men who are unlikely to 
benefit.
The classical pathway for the diagnosis of prostate 
cancer is transrectal ultrasound-guided (TRUS) biopsy of 
the prostate following a raised prostate-specific antigen 
(PSA). TRUS guidance is performed primarily for 
anatomical guidance and the ultrasound discriminates 
poorly between cancerous and non-cancerous tissues.3 
Biopsies are concentrated in areas of the peripheral zone, 
thought to harbour the majority of cancers.4
An alternative pathway for the diagnosis of prostate 
cancer in men with raised PSA is to perform a multi-para-
metric MRI (MPMRI) to localise cancer and to use this 
information to influence both the decision for and 
conduct of a subsequent biopsy, known as an MPMRI-tar-
geted biopsy. MPMRI has demonstrated good diagnostic 
performance for the detection of clinically significant 
cancer.5 MPMRI-targeted biopsy has been shown to detect 
a similar or greater amount of clinically significant cancer 
to TRUS biopsy but avoid the detection of a greater 
proportion of clinically insignificant cancer, which may 
not benefit from treatment.6 Robust level 1 evidence from 
appropriately powered studies comparing MPMRI-tar-
geted biopsy to TRUS biopsy in a pragmatic multicentre 
setting is lacking.
If MPMRI-targeted biopsy leads to fewer men being 
biopsied with fewer biopsy cores, no fewer clinically signif-
icant cancers identified but fewer insignificant cancers 
identified, then an MPMRI-driven diagnostic pathway 
could replace TRUS biopsy as the standard of care for 
prostate cancer diagnosis.
objectives
The primary objective is to assess whether MPMRI-tar-
geted biopsy is non-inferior to standard 10–12-core TRUS 
biopsy in the diagnosis of clinically significant prostate 
cancer in men referred with clinical suspicion of prostate 
cancer who have had no prior prostate biopsy.
Key secondary objectives include:
 ► To assess whether MPMRI-targeted biopsy detects 
fewer men with clinically insignificant prostate cancer 
than 10–12-core TRUS biopsy
 ► To assess the proportion of men in the MRI arm who 
avoid biopsy
trial design
This is a pragmatic, international, multicentre, parallel 
group, non-inferiority randomised study in which men 
are allocated in a 1:1 ratio to MPMRI or to TRUS biopsy. 
This is the first trial to randomise men to an MRI arm in 
which targeted biopsy alone is carried out in the presence 
of an MRI lesion (ie, no biopsies of MRI-normal areas of 
prostate) and in which no biopsy at all is carried out if 
the MRI is non-suspicious (figure 1). The comparator of 
TRUS biopsy has been chosen as this is currently the stan-
dard of care in the majority of institutions.
A randomised trial design was chosen rather than a 
paired cohort design for the following reasons:
 ► In order to reduce performance bias that can result 
from carrying out one test after another as the conduct 
of one test may influence conduct of the other when 
both are carried out in the same patient.
 ► To allow the assessment of adverse events (AEs) asso-
ciated with each technique.
 ► To allow the assessment of the patient's willingness to 
remain on their allocated pathway.
 ► To allow the assessment of the physician's willingness 
to adhere to the allocated pathway.
 ► To allow patients to potentially benefit by having a 
biopsy with fewer biopsy cores.
 ► To allow patients to potentially benefit by avoiding a 
biopsy and its complications altogether.
There is no gold standard reference test that is appli-
cable to all patients referred with suspected prostate 
cancer. As radical prostatectomy is only performed in a 
small proportion of patients who test positive on the index 
test, it is therefore not an appropriate reference test. 
Therefore, a comparison of cancer detection between 
each approach was chosen as the primary outcome of 
interest.
MEthods And AnAlysIs
study setting
Hospitals which perform MPMRI-targeted and TRUS 
biopsy will take part in the study. Some of these centres 
will be from the Standards of Reporting for MRI-targeted 
Biopsy Studies (START) consortium,7 though non-START 
consortium centres are permitted to take part providing 
prior detection rates from the biopsy procedures in their 
practice are approved by the chief investigator prior to 
starting the study at their centre.
We expect centres from the following countries to take 
part: Argentina, Belgium, Canada, Finland, France, Italy, 
Germany, the Netherlands, Switzerland, UK and the USA.
Eligibility criteria
Patients will be considered eligible for registration into 
this study if they fulfil all of the inclusion criteria and 
none of the exclusion criteria, as defined in box 1. The 
key eligibility criteria include serum PSA ≤20 ng/mL, 
suspected tumour stage ≤T2 on rectal examination and 
no prior prostate biopsy.
Interventions
MPMRI arm
MPMRI will be carried out using a 1.5 Tesla or 3.0 
Tesla scanner with a pelvic phased array coil and power 
injector for contrast administration with the patient in 
the supine position. T2-weighted, diffusion weighted and 
dynamic contrast enhanced scans will be acquired as per 
the minimum requirements set out by consensus guide-
lines.8 The site performing the MPMRI should provide 
specific detailed information on their MRI scanners and 
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Figure 1 PRECISION Trial schema.
box 1 Eligibility criteria
Inclusion criteria
1. Men at least 18 years of age referred with clinical suspicion of 
prostate cancer who have been advised to have a prostate biopsy
2. Serum prostate-specific antigen (PSA) ≤20 ng/mL
3. Suspected stage ≤T2 on rectal examination (organ-confined 
prostate cancer)
4. Fit to undergo all procedures listed in the protocol
5. Able to provide written informed consent
Exclusion criteria
1.  Prior prostate biopsy
2.  Prior treatment for prostate cancer
3.  Contraindication to MRI (eg, claustrophobia, pacemaker, estimated 
glomerular filtration rate ≤50 mls/min)
4.  Contraindication to prostate biopsy
5.  Men in whom artefact would reduce the quality of the MRI
6.  Previous hip replacement surgery, metallic hip replacement or 
extensive pelvic orthopaedic metal work
7.  Unfit to undergo any procedures listed in the protocol
protocols in advance which need to be approved by the 
PRECISION Operations Group prior to participating in 
the study.
The MPMRI will be reported by an experienced nomi-
nated radiologist using a dedicated MRI reporting pro 
forma. Prior experience of the radiologists must be 
provided in advance and approved by the PRECISION 
Operations Group prior to the site being able to partic-
ipate in the study. The MPMRI will be scored based on 
consensus recommendations8 9 employing a 1–5 score of 
suspicion:
Suspicious areas in the prostate will be scored on the 
following scale:
 ► 1 = Highly unlikely to be clinically significant cancer
 ► 2 = Unlikely to be clinically significant cancer
 ► 3 = The presence of clinically significant cancer is 
equivocal
 ► 4 = Likely to be clinically significant cancer
 ► 5 = Highly likely to be clinically significant cancer
MPMRI-targeted biopsy
A participant with a prostate that contains a suspicious 
area with an MPMRI score of 3, 4 or 5 will subsequently 
undergo targeted biopsy by a clinician experienced in 
MPMRI-targeted biopsy. The experience of the clinicians 
performing biopsy must be provided to the PRECISION 
Operations Group in advance and approved prior to the 
site participating in the study.
A maximum of three MRI-suspicious areas will be 
chosen for targeted biopsy with a maximum of 4 cores to 
be taken per suspicious area and a maximum of 12 cores 
in total. Targeted biopsies can be performed by visual 
registration or software-assisted registration, as described 
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Table 1A Participant timeline in the study: the timeline for men randomised to TRUS biopsy
Contact with patient
Visit 0* Visit 1 Visit 2 Visit 3 Visit 4
Weeks: −1 0 1 2 6
Teleconsult X Not required
Consent X
Screening X
Randomisation X
EQ-5D-5L X X X
Optional urine, blood and semen samples X
TRUS biopsy X
MRI
MPMRI-targeted biopsy
Immediate post-MRI questionnaire
Immediate post biopsy questionnaire X
Follow-up for results of tests X
Treatment decision† X
30-day post biopsy questionnaire X
30-day post-MRI questionnaire
SAE Complete as required at any time following registration
Withdrawal form Complete as required at any time following registration
*This visit is optional depending on local site referral procedures. It is carried out over the phone 1 week prior to the first face-to-face visit.
†After treatment decision men revert to standard of care.
MPMRI, multi-parametric MRI; SAE, serious adverse event, TRUS, transrectal ultrasound-guided.
previously,7 and can be carried out transrectally or trans-
perineally, according to local expertise.
No target identified on MPMRI
A participant with a prostate that contains no suspicious 
areas on MPMRI (ie, scoring 1 or 2) will not undergo a 
biopsy as part of the protocol.
TRUS biopsy arm
All participants in this arm will undergo a standard 10–12-
core TRUS biopsy as described previously.10 The patient 
will be positioned in the left lateral position and 10–12 
cores will be taken from the peripheral zone of the apex, 
mid-gland and base of the prostate on the right and left 
sides.
The experience of the clinicians performing the biopsy 
must be provided to the PRECISION Operations Group 
in advance and approved prior to the site participating in 
the study.
Patient-reported outcome measures
In both arms self-reported questionnaires to capture 
biopsy-specific side effects will be completed immediately 
postprocedure, and at 30 days. Health-related quality of 
life EQ-5D-5L questionnaires will also be completed at 
baseline, 24 hours post-MRI, 24 hours post biopsy and 30 
days post intervention.
Treatment decision and participant timeline
A clinician reviews participants with results of the test 
and treatment decisions are made according to local 
standard of care. If a further biopsy, further MPMRI or 
any other diagnostic test is requested from the treatment 
decision visit or if the clinician books a radical prosta-
tectomy, then the result of the procedure is recorded, 
after which the man completes the study. Otherwise men 
complete the study after the treatment decision visit or 
when the 30-day questionnaires are completed, which-
ever is later.
Providing the interventions occur in the specified 
sequence order, there is no necessitated timeline within 
which the interventions must occur as this is dependent 
on local resources, but it is expected that the majority of 
patients will complete the study within 6 weeks of enrol-
ment (table 1A,B,C).
Interventions—strategies to improve adherence to intervention 
protocols
After the treatment decision has been made, clinicians 
are permitted to order the test that the patient was not 
randomised to and participants are aware of this when 
enrolling in the study.
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Table 1B Participant timeline in the study: the timeline for men randomised to MPMRI who require an MPMRI-targeted biopsy
Contact with patient
Visit 0* Visit 1 Visit 2 Visit 3 Visit 4
Weeks: −1 0 1 2 6
Teleconsult X
Consent X
Screening X
Randomisation X
EQ-5D-5L X X X X
Optional urine, blood and semen samples X
TRUS biopsy
MRI X
MPMRI-targeted biopsy X
Immediate post-MRI questionnaire X
Immediate post biopsy questionnaire X
Follow-up for results of tests X
Treatment decision† X
30-day post biopsy questionnaire X
30-day post-MRI questionnaire
SAE Complete as required at any time following registration
Withdrawal form Complete as required at any time following registration
*This visit is optional depending on local site referral procedures. It is carried out over the phone 1 week prior to the first face-to-face visit.
†After treatment decision men revert to standard of care.
MPMRI, multi-parametric MRI; SAE, serious adverse event, TRUS, transrectal ultrasound-guided.
Participants are given reminders by the trial teams for 
completion of questionnaires at the correct time.
Interventions—concomitant care
Relevant anticoagulant/antiplatelet medication will be 
discontinued up to 10 days before biopsy and advice 
sought as to appropriate substitutes if indicated. Aspirin 
will be continued at the discretion of the physician doing 
the biopsy.
Participants may otherwise continue with any other 
concomitant care that they were receiving prior to 
enrolling on the study.
Withdrawal of individual participants
Participants can discontinue the participation of the 
study at any time for any reason. Data up to the time of 
withdrawal can be included in the study.
outcomes
Primary outcome
Proportion of men with clinically significant cancer 
detected. This will be evaluated on a per patient basis from 
needle biopsy. The primary definition will be a single core 
containing Gleason grade 3+4 disease or greater.
Time frame for assessment: when histology results 
are available, at an expected average of 30 days post 
intervention.
Secondary outcomes
Please see table 2 for a full list of secondary outcomes.
Sample size
Rates of clinically significant cancer detection from target-
ed-alone biopsy in a population with no prior biopsy have 
been shown to be 50%.11 Assuming 20% of men avoid 
biopsy in the MRI arm of PRECISION, this would corre-
spond to a 50% detection rate in 80% of the participants 
in this arm =40% overall detection rate of clinically signif-
icant cancer in the MRI arm.
Rates of clinically significant cancer detection from 
one of the largest studies of TRUS biopsy in men without 
prior biopsy are shown to be 27%.12
For the non-inferiority hypothesis, using 90% power 
and 2.5% one-sided α, using an estimate for detection 
rate of clinically significant cancer for targeted biopsy of 
40% and an estimate of detection rate for TRUS biopsy 
of 30% and using a margin of clinical unimportance of 
5%, 211 men per arm will be required. The choice of 5% 
as the margin of non-inferiority represents a difference 
that would be considered clinically unimportant in the 
detection rates.
Thus the total men required in the study is 422.
Accounting for 10% withdrawal/loss to follow-up, 470 
men will need to be recruited.
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Table 1C Participant timeline in the study: the timeline for men randomised to MPMRI who have no suspicious areas on MRI 
and do not require a biopsy
Contact with patient
Visit 0* Visit 1 Visit 2 Visit 3 Visit 4
Weeks: −1 0 1 2 5
Teleconsult X Not required
Consent X
Screening X
Randomisation X
EQ-5D-5L X X X
Optional urine, blood and semen samples X
TRUS biopsy
MRI X
MPMRI-targeted biopsy
Immediate post-MRI questionnaire X
Immediate post biopsy questionnaire
Follow-up for results of tests X
Treatment decision† X
30-day post biopsy questionnaire X
30-day post-MRI questionnaire X
SAE Complete as required at any time following registration
Withdrawal form Complete as required at any time following registration
*This visit is optional depending on local site referral procedures. It is carried out over the phone 1 week prior to the first face-to-face visit.
†After treatment decision men revert to standard of care.
MPMRI, multi-parametric MRI; SAE, serious adverse event, TRUS, transrectal ultrasound-guided.
Table 2 Secondary outcomes in PRECISION
Outcome Time frame for assessment
Proportion of men with clinically insignificant cancer (Gleason 
grade 3+3) detected
When histology results available, at an expected average of 
30 days post intervention
Proportion of men in the MPMRI arm who avoid biopsy When MRI results available, at an expected average of 30 days 
post-MRI
Proportion of men in whom the MPMRI score for suspicion 
of clinically significant cancer was 3, 4 or 5 but no clinically 
significant cancer was detected
When histology results available, at an expected average of 
30 days post biopsy
Proportion of men who go on to definitive local treatment 
(eg, radical prostatectomy, radiotherapy, brachytherapy) or 
systemic treatment (eg, hormone therapy, chemotherapy)
After treatment decision, at an expected average of 30 days 
post biopsy
Cancer core length of the most involved biopsy core 
(maximum cancer core length, mm)
When histology results available, at an expected average of 
30 days post intervention
Proportion of men with post biopsy adverse events 30 days post biopsy
Health-related quality of life Baseline, 24 hours post intervention and 30 days post 
intervention
Proportion Gleason grade upgrading in men undergoing 
radical prostatectomy
An expected average of 90 days post biopsy
Cost per diagnosis of cancer 30 days post biopsy
MPMRI, multi-parametric MRI.
Recruitment
Enrolment will take place at the outpatient clinics of the 
participating medical centres. Prior to being approved to 
take part in the study, participating sites are required to 
confirm that they have enough eligible patients attending 
their centre to be able to recruit approximately three 
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Table 3 WHO trial registration data set
Data category Information
Primary registry and trial 
identifying number
ClinicalTrials.gov: NCT02380027
Date of registration in the 
primary registry
23 February 2015
Secondary identifying 
numbers
ISRCTN: 18440098
Source(s) of monetary or 
material support
National Institute for Health and Research UK (DRF-2014-07-146)
European Association of Urology Research Foundation
Primary sponsor University College London
Secondary sponsor(s) N/A
Contact for public queries Mr Veeru Kasivisvanathan veeru.kasi@ucl.ac.uk
Urology Research Group,
Room 4.23, Fourth floor,
132 Hampstead Road,
London,
NW1 2PT
Tel:+44 (0)207 679 9092, Fax:+44 (0)207 679 9511
Contact for scientific queries Mr Veeru Kasivisvanathan veeru.kasi@ucl.ac.uk
Urology Research Group,
Room 4.23, Fourth floor,
132 Hampstead Road,
London,
NW1 2PT
Tel:+44 (0)207 679 9092, Fax:+44 (0)207 679 9511
Public title/short title Prostate evaluation for clinically important disease: sampling using image guidance or not?
Acronym PRECISION
Scientific title A randomised control trial of MRI-targeted biopsy compared with standard TRUS biopsy for the 
diagnosis of prostate cancer in men without prior biopsy
Countries of recruitment Argentina
Belgium
Canada
Finland
France
Italy
Germany
Netherlands
Switzerland
UK
USA
Health condition(s) or 
problem(s) studied
Prostate neoplasm
Intervention(s) Device: MRI. This will be a multi-parametric MRI of the prostate.
Procedure: MRI-targeted biopsy. This will be a biopsy targeted to suspicious areas on the MRI.
Procedure: TRUS biopsy. This will be a standard 12-core transrectal prostate biopsy.
Intervention description 1. Experimental: MRI-arm
Men in this arm will undergo multi-parametric MRI. In the presence of a suspicious area, a man 
will undergo MRI-targeted biopsy with cores targeted to the suspicious lesion. In the absence of 
a suspicious area, no biopsy will be taken.
Interventions:
Device: MRI
Procedure: MRI-targeted biopsy
2. Active comparator: TRUS biopsy arm
Men in this arm undergo standard 12-core TRUS prostate biopsy.
Intervention:
Procedure: TRUS biopsy
Continued
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Data category Information
Key inclusion and exclusion 
criteria
Inclusion criteria:
1. Men at least 18 years of age referred with clinical suspicion of prostate cancer who have been 
advised to have a prostate biopsy
2. Serum PSA ≤20 ng/mL within the previous 3 months
3. Suspected stage ≤T2 on rectal examination (organ-confined prostate cancer) within the 
previous 3 months
4. Fit to undergo all procedures listed in the protocol
5. Able to provide written informed consent
Exclusion criteria:
1. Prior prostate biopsy
2. Prior treatment for prostate cancer
3. Contraindication to MRI (eg, claustrophobia, pacemaker, estimated glomerular filtration rate 
≤50 mls/min)
4. Contraindication to prostate biopsy
5. Men in whom artefact would reduce the quality of the MRI
6. Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic 
metal work
7. Unfit to undergo any procedures listed in the protocol
Study type Interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: statistician
Primary purpose: diagnostic
Sequence generation: bespoke SAS programme
Block randomisation
Achievement of allocation concealment: only authorised staff members have access to the 
allocation sequence. No investigators have access to the sequence. The allocation for the next 
patient is given by an authorised staff member or electronically after the investigator confirms 
that the eligibility criteria for inclusion of that patient have been met.
Date of first enrolment 10 February 2016
Target sample size 470
Recruitment status Recruiting
Primary outcome(s) Proportion of men with clinically significant detected
Key secondary outcomes  ► Proportion of men with clinically insignificant cancer detected (time frame: when histology 
results are available, at an expected average of 30 days post biopsy)
 ► Proportion of men in the MRI arm who avoid biopsy (time frame: when MRI results are 
available, at an expected average of 30 days post-MRI)
 ► Proportion of men with an MRI score 3, 4 or 5 who have no clinically significant cancer 
detected (time frame: when histology results are available, at an expected average of 30 days 
post biopsy)
 ► Proportion of men who go on to definitive treatment for prostate cancer (time frame: after 
treatment decision, at an expected average of 30 days post biopsy)
 ► Definitive treatment can be localised (eg, radical prostatectomy, radiotherapy, brachytherapy) 
or systemic (hormone therapy, chemotherapy)
 ► Cancer core length in mm of the most involved biopsy core (maximum cancer core length) 
(time frame: when histology results available, at an expected average of 30 days post biopsy)
 ► Proportion of men with post biopsy adverse events (Time frame: 30 days post biopsy)
 ► EQ-5D-5L Quality of Life Scores (time frame: baseline, 24 hours post intervention and 30 days 
post intervention)
 ► Proportion of men undergoing radical prostatectomy who have Gleason grade upgrading (time 
frame: an expected average of 90 days post biopsy)
 ► Cost per diagnosis of cancer (time frame: 30 days post biopsy)
PSA, prostate-specific antigen; TRUS, transrectal ultrasound-guided.
Table 3 Continued 
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Table 4 Revision chronology for amendments to protocol
Protocol version 
and date Reasons for amendments
V.1.0, issued 11 
April 2015
Original protocol
V.1.1, issued 24 
May 2015
Main reasons for amendment: minor changes in the patient information sheet to ensure compliance with 
research ethics committee regulations. Main changes:
1. Version number and date added to all pages
2. Patient advice and liaison service contact details specified
3. Sentence changed from ‘different treatment’ to ‘a different diagnostic test’
4. The name of the approving research ethics committee added ‘NRES Committee East Midlands - 
Leicester’
V.1.2, issued 26 
August 2015
Main reasons for amendment: minor changes to make existing trial documents clearer. Main changes:
1. International Standard Registered Clinical/soCial sTudy Number (ICRCTN) number and UK Clinical 
Research Network(CRN) identifiers added.
2. Wording in Section 17.3 Assessment of Safety. Wording clarified to ensure it is clear which expected 
adverse events do not need to be reported.
3. Updates of sites and PIs participating in the trial.
4. Clarification in TRUS biopsy conduct section 11.2. TRUS biopsy as described in the protocol allows 
10–12 cores to be taken. Although this was clear in the protocol, this is clarified throughout the text now 
as the procedure is often quoted as 12-core biopsy, which may otherwise be confusing to the PI.
5. Appendix 7—EQ-5D—update of copyright date from 1990 to 2009. No change in content.
6. In the ‘What will happen to me if I take part’ section, clarification that the timelines are suggested 
timelines and that timelines for trial procedures depend on clinical workload at the hospital.
PI, principal investigator; TRUS, transrectal ultrasound-guided.
men per month. With at least 11 participating centres, it 
is estimated that the study will complete within 26 months 
of commencement. The start date of the study is February 
2016 and the estimated completion date for recruitment 
is April 2018.
Randomisation and treatment allocation
Participants are randomised in a 1:1 ratio to either MPMRI 
or TRUS biopsy. Randomisation will be executed per 
participant, by web-based block randomisation after the 
informed consent procedure is completed. The Univer-
sity College London (UCL) Surgical and Interventional 
Trials Unit will facilitate the randomisation.
Sequence generation
Randomisation schedules are be prepared by a member 
of the UCL Surgical and Interventional Trials Unit using 
a bespoke SAS programme, with equal allocation between 
treatment arms using random permuted blocks of varying 
size, stratified by centre.
Allocation concealment
Only authorised staff members within the UCL Surgical 
and Interventional Trials Unit and the authorised staff 
member who uploads the sequence to the web-based 
randomisation service have access to the allocation 
sequence. None of these staff members are involved in 
clinical patient contact. The investigators responsible for 
patient recruitment who do have clinical patient contact 
do not have access to the sequence and are unaware of the 
block sizes. The allocation for the next patient is given on 
a patient by patient basis by an authorised staff member 
or electronically by the web-based system.
Blinding
In this trial, blinding of the participant or the clinician is 
not feasible. While the study is progressing, for any clin-
ical outcomes that come to the attention of the PRECI-
SION Operations Group (eg, serious adverse events 
(SAEs)), the main study statistician will be blinded as to 
which group these outcomes are from. Where feasible, 
when analysing the outcome data from the study, the 
study statistician will be blinded to the groups until the 
end of the analysis.
Data management
To ensure high quality trial conduct, data management 
will be carried out according to the principles of the 
International Council of Harmonisation Good Clinical 
Practice. Data will be entered onto a web-based MARVIN 
e-case report form (eCRF) system which increases data 
quality. Quality control is carried out routinely; data 
types, entries and permitted ranges for answers to every 
question on the eCRFs are restricted on this web-based 
system. Automatic validation checks and automatic 
queries are raised by the system immediately to indi-
vidual sites in the case of any queries. Authorised indi-
viduals from the PRECISION Operations Group may 
also check the data for quality and may pose manual 
queries to the site to address. A proportion of partici-
pating sites’ MRI and histopathology data may be veri-
fied centrally.
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Table 5 Roles and responsibilities in the PRECISION Trial
Role Details and responsibilities
Trial sponsor University College London (UCL)
Sponsor’s reference: UCL REDA Number 15/0299
Contact name: Susan Tebbs
Address:
Comprehensive Clinical Trials Unit (CCTU)
UCL,
Gower Street,
London,
WC1E 6BT
Telephone: 020 3447 5557
Email: Rand.D@uclh.nhs.uk
The trial sponsor did not provide any funding for the study. University College London has the role of research 
governance sponsor of PRECISION. UCL adopted the study as sponsor after the UCL CCTU carried out a 
trial adoption process which involved the UCL CCTU reviewing the protocol to ensure it conformed to high 
standards of trial conduct and met the governance requirements of UCL. The UCL CCTU is responsible for 
oversight of the trial. The sponsor plays no role in data collection, management, analysis and interpretation of 
data, writing of the report or the decision to submit the report for publication.
PRECISION 
Operations 
Group
The PRECISION Operations Group consists of the chief investigators, the study coordinator, the UCL Surgical 
and Interventional Trials Unit and the eCRF database managers. This group is responsible for:
 ► Study planning
 ► Preparation of protocol and revisions
 ► Assistance with international review board/independent ethics committee applications
 ► Preparation of investigators brochure and CRFs
 ► Organisation of steering committee meetings
 ► Provide annual progress reports to the ethics committee
 ► Reporting serious adverse events to the sponsor and ethics committee when necessary
 ► Responsible for trial master file
 ► Budget administration and contractual issues with individual centres
 ► Advice for PIs
 ► Site initiation visits
 ► Randomisation
 ► Data verification and management
 ► Central monitoring and resolving data queries with clinicians and nurses at the trial sites
 ►Maintenance of the trial Information Technology (IT) system
 ► Publication of study reports
PI At each participating site, the PI is responsible for the conduct of the clinical trial to ensure the safety of 
participants and the reliability and robustness of the data generated. They will be responsible for identification, 
recruitment, data collection and completion of CRFs, along with follow-up of study patients and adherence to 
study protocol and investigators brochure. The PI as leader of the research team may delegate his/her duties to 
members of his/her team.
 GTSC Consists of a team independent of the PRECISION Operations Group and independent of the PIs. It comprises 
independent chairs, advisory board members and chief investigators. Observers from the Clinical Trials Group 
are present during meetings. The GTSC’s role is to:
1. To monitor and supervise the progress of the study towards its overall objectives at regular intervals
2. To consider the recommendations of the DMC and make recommendations on future study conduct
DMC Consists of an independent chair, clinical representative, patient representative and statistician. The DMC’s role 
is to safeguard the interests of trial participants and monitor the overall conduct of the clinical trial. The DMC is 
independent of, but reports to, the GTSC.
CRF, case report form; DMC, Data Monitoring Committee; GTSC, Global Trial Steering Committee; PI, principal investigator.
The data will be stored by the PRECISION Operations 
Group for 20 years after the final publication from the 
trial. Further details on data storage, curation and destruc-
tion are available in a separate document on request to 
the UCL Surgical and Interventional Trials Unit.
Data collection methods
An eCRF user guide has been produced to aid sites in 
completing all eCRFs. Sites are required to confirm 
in writing that they have practised entering imaginary 
patient data for all eCRFs into a demo version of the 
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MARVIN eCRF system prior to being granted approval to 
use the live MARVIN eCRF system. Only authorised users 
of the system on the local site delegation log have access 
to the MARVIN system. Details on how to collect data in 
the study are given in a mandatory site initiation visit. The 
content of the presentation must be viewed by all local 
site staff.
Baseline patient and follow-up data will be recorded by 
authorised individuals from clinical encounters during 
the study. Self-reported, previously validated EQ-5D-5L 
questionnaires will be used to assess health-related quality 
of life.13 Post biopsy complications will be assessed by 
self-reported questionnaires based on previously vali-
dated questionnaires.14
Participant retention
Once a participant is enrolled or randomised, the local 
site will make every reasonable effort to follow the patient 
for the entire study period. It is estimated that loss to 
follow-up/withdrawal after randomisation will be no 
more than 10%. Study site staff are responsible for devel-
oping and implementing local standard operating proce-
dures to achieve this.
Statistical methods
The formal statistical analysis plan will be finalised before 
database lock and before any statistical analysis.
A consort diagram will be presented. All continuous 
variables will be described using the mean, SD, median, 
minimum and maximum. Categorical variables will be 
described using frequencies and proportions.
The statistical assumptions underpinning each method 
will be checked. The use of transformations or non-para-
metric methods will be considered to satisfy statistical 
assumptions.
Primary outcome analysis
The primary analysis will be based on an intention to treat 
sample as well as a per protocol sample.
Our primary end point is the difference in proportion 
of men with clinically significant cancer detected between 
the two groups.
Absolute differences in proportion of clinically signifi-
cant cancer detected between arms will be calculated with 
95% CIs.
If the lower bound of the 97.5% CI for the difference in 
detection rates of MPMRI+/- targeted biopsy compared 
with TRUS biopsy is greater than −5% then MPMRI+/-- 
targeted biopsy will be deemed non-inferior.
In the event that the lower bound is greater than zero, 
superiority can be claimed.
Baseline characteristics will be compared between the 
two groups. Any imbalance found between the groups will 
be accounted for in a multivariable logistic regression anal-
ysis. This model will include clinically significant cancer 
as the dependant variable, group as the independent vari-
able and any characteristics with baseline imbalance as a 
covariate. Potential confounders identified a priori will 
also be considered in the model described here. Here, 
the effect of centre will also be explored using a mixed 
logistic regression model with clinically significant cancer 
as the dependant variable, group as the independent vari-
able and centre as a random effect.
The effect of missing data will be explored and dealt 
with in an appropriate manner.
Secondary outcome analyses
The effect sizes will be presented with 95% CIs.
For binary outcomes, absolute differences in propor-
tion between arms will be calculated with 95% CIs. Any 
imbalance found between the groups will be accounted 
for in a multivariable logistic regression analysis.
For continuous outcomes, mean differences in 
outcomes between arms will be calculated with 95% 
CIs. Any imbalance found between the groups will be 
accounted for in a multivariable linear regression anal-
ysis. Where the outcomes are not normally distributed, 
a suitable transformation or non-parametric test will be 
considered.
Descriptive analysis
Where a patient after receiving the per protocol treat-
ment receives another test which leads to further knowl-
edge about the presence or absence of cancer, this will be 
described. The number of false positives and false nega-
tives will be recorded.
Monitoring
The Global Trial Steering Committee (GTSC) consists 
of a team independent of the PRECISION Operations 
Group and independent of the principal investigators 
(PIs). It comprises chairs, advisory board members and 
chief investigators. Observers from the UCL Surgical and 
Interventional Trials Unit are present during meetings. 
The GTSC’s role is to:
1. To monitor and supervise the progress of the study 
towards its overall objectives at regular intervals
2. To consider the recommendations of the Data 
Monitoring Committee (DMC) and make 
recommendations on future study conduct
The DMC consists of an independent chair, clinical 
representative, patient representative and statistician. 
The DMC’s role is to safeguard the interests of trial partic-
ipants and monitor the overall conduct of the clinical trial. 
The DMC is independent of, but reports to, the GTSC. 
They will meet at regular intervals throughout the study 
period as determined by the chair, but as a minimum at 
least once every 12 months.
The DMC Charter can be obtained by request to the 
Surgical and Interventional Trials Unit.
The sponsor may also arrange an independent trial 
monitor to audit the study data.
Harms
AEs will be defined as 'any untoward medical occurrence 
in a clinical trial subject undergoing any intervention in 
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the trial, which does not necessarily have a causal rela-
tionship with this treatment’.
SAEs will be defined as 'any untoward medical occur-
rence as a result of any intervention in the trial that:
 ► results in death,
 ► is life-threatening
 ► requires hospitalisation or prolongation of existing 
inpatients' hospitalisation, results in persistent or 
significant disability or incapacity’
AEs and SAEs will be recorded until 30 days post biopsy. 
In the event that the patient does not undergo biopsy, 
AEs and SAEs should be recorded until 30 days post-MRI.
AEs will be recorded by a member of the research team 
or clinical team on an AE report form eCRF. All SAEs 
must be recorded on an SAE report form eCRF within 
24 hours of knowledge of the SAE. Both AEs and SAEs 
should be recorded in the medical notes. Completed AE 
and SAE report forms should be sent to the UCL Surgical 
and Interventional Trials Unit, who will keep a log of AEs 
and SAEs. AE and SAE logs will be reviewed by the DMC.
Ethics and dissemination
The protocol and each participating site will have Research 
Ethics Committee (REC) approval before participants are 
entered. The UK National REC (NRES Committee East 
Midlands, Leicester) gave favourable approval for study 
on 3 June 2015 (Ref:15/EM/0188).
Amendments to the protocol will be made after ethical 
approval by the research ethics committee in each respec-
tive centre. Centres will be notified immediately after any 
protocol amendments.
Consent
The clinical teams managing patients with suspected 
prostate cancer who are referred to their centre will iden-
tify potential trial participants. Patient information sheets 
will be provided to patients. Members of staff who are 
trained to take written informed consent, as indicated by 
the PI on the delegation log for that site, will take written 
informed consent in a face-to-face visit. A model consent 
form is shown in online supplementary appendix 1 and 
a model patient information sheet is shown in online 
supplementary appendix 2.
Additional ethics-approved consent will be sought 
from patients for collection of biological samples (blood, 
urine, semen), pending additional funding being secured 
for collection and processing of samples. If funding is 
secured, these samples will be stored in the UCL/Royal 
Free Biobank for use in future biomarker studies (supple-
mentary appendix 3).
Confidentiality
The data of the participants will be recorded into the 
eCRF system and analysed without any personal identi-
fiers, by using coded information. The source documents 
and identification lists will be archived in a secured 
facility per centre. Permission for accessing data will be 
documented per investigator.
Dissemination
Results of this study will be disseminated through national 
and international conferences and papers. Authorship 
criteria will be based on recommendations of the Inter-
national Committee of Medical Journal Editors. The 
participants and relevant patient support groups will be 
informed about the results of the study.
Access to data
Only authorised individuals within the PRECISION Oper-
ations Group have access to the final data set. Individual 
PIs have access to their own data but not that of other 
sites.
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